- Assistant Professor of Psychiatry and Psychology
- Associate Director of Translational Research in Women’s Mental Health
- Department of Psychiatry
- University of Illinois at Chicago College of Medicine
- temo [at] uic.edu
- (312) 996-9619
- (312) 413-4265
Neuropsychiatric Institute (NPI)
912 S. Wood St.
Department of Psychiatry (MC 913)
Chicago IL 60612
- Room #:335
Dr. Eisenlohr-Moul joins the Women’s Mental Health Research Program in January 2018.
Dr. Eisenlohr-Moul is a clinical scientist studying emotional, cognitive and behavioral responses to changing hormones across the menstrual cycle. Primary outcomes of interest are suicidality, substance abuse, and dysregulated interpersonal functioning (e.g., the interpersonal symptoms of borderline personality disorder or BPD).
The first focus of the Eisenlohr-Moul laboratory is the use of experimental clinical trial methods to examine the effects of perimenstrual withdrawal from estradiol, progesterone, and their neurosteroid metabolites (e.g., allopregnanolone) on acute suicide risk. Early experimental data from Dr. Eisenlohr-Moul’s K99 award indicates that perimenstrual hormone stabilization (vs. withdrawal under placebo) prevents perimenstrual risk for acute suicidality. Further work will compare the effects of estradiol and progesterone stabilization, and will probe various potential neurobiological mediators of these experimental effects. This program of research may help to clarify the basic neurobiological mechanisms of acute changes in suicide risk for both females and males, and may eventually lead to the development of treatments that anticipate and prevent suicide attempts among at-risk individuals.
The second focus of the laboratory is the identification, characterization, and reliable diagnosis of subtypes of psychiatric symptom change across the menstrual cycle. At the diagnostic level, this includes the development of reliable methods for differential diagnosis of (1) the new DSM-5 diagnosis of premenstrual dysphoric disorder (PMDD), (2) perimenstrual exacerbation of underlying psychiatric disorder (e.g., BPD), and (3) PMDD with comorbid psychiatric diagnoses. During her fellowship in reproductive mood disorders, Dr. Eisenlohr-Moul developed and published the Carolina Premenstrual Assessment Scoring System (or C-PASS), the first fully standardized computerized method for making the new DSM-5 diagnosis of Premenstrual Dysphoric Disorder using two months of daily symptom ratings. Dr. Eisenlohr-Moul also works with large observational datasets of daily symptom data to examine potential symptom timing subgroups within each of these diagnostic categories that may help to clarify individual differences in the pathophysiologic underpinnings of perimenstrual symptoms that cut across the above diagnostic categories (e.g., early luteal vs. late luteal symptom onset). This work may inform the development of targeted treatments based on the reliable assessment of individual differences in perimenstrual symptom change dynamics.
Dr. Eisenlohr-Moul received her PhD in Clinical Psychology in 2014 from the University of Kentucky, where her training emphasized translational clinical science, endocrine and immune factors in psychopathology, and advanced statistics. She completed her clinical internship at Duke University Medical Center from 2013-2014 in full-model Dialectical Behavior Therapy, a highly-structured, evidence-based treatment for adults presenting with chronic suicidality. From 2014-2017, Dr. Eisenlohr-Moul received intensive postdoctoral training in the pathophysiology of reproductive mood disorders (premenstrual dysphoric disorder, perinatal mood disorder, and perimenopausal mood disorder) at the Center for Women’s Mood Disorders at the University of North Carolina at Chapel Hill. She received a prestigious K99/R00 award from the National Institute of Mental Health in 2016; her work at UIC will begin in 2018 with completion of an R00-funded experiment.
Menstrual cycle effects on mental health, perimenopausal depression, perinatal mental health, estradiol, progesterone, testosterone, GABAergic neurosteroids, psychoneuroimmunology, suicide, substance abuse, interpersonal functioning, impulsive and compulsive disorders, premenstrual dysphoric disorder (PMDD), perimenstrual exacerbation of underlying disorder (PME), borderline personality disorder (BPD) assessment and diagnosis, Dialectical Behavior Therapy (DBT), women’s mental health
Eisenlohr-Moul TA, Girdler SS, Johnson JL, Schmidt PJ, Rubinow DR. Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial. Depress Anxiety. 2017 Oct; 34(10): 908-917. PMC5629109
Eisenlohr-Moul TA, Girdler SS, Schmalenberger KM, Dawson DN, Surana P, Johnson JL, Rubinow DR. Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS). Am J Psychiatry. 2017 Jan 1; 174(1): 51-59. PMC5205545
Roberts B, Eisenlohr-Moul T, Martel MM. Reproductive steroids and ADHD symptoms across the menstrual cycle. Psychoneuroendocrinology. 2017 Nov 28; 88: 105-114. PMID: 29197795
Martel MM, Eisenlohr-Moul T, Roberts B. Interactive effects of ovarian steroid hormones on alcohol use and binge drinking across the menstrual cycle. J Abnorm Psychol. 2017 Nov; 126(8): 1104-1113. PMID: 29154570
Dawson DN, Eisenlohr-Moul TA, Paulson JL, Peters JR, Rubinow DR, Girdler SS. Emotion-related impulsivity and rumination predict the perimenstrual severity and trajectory of symptoms in women with a menstrually related mood disorder. J Clin Psychol. 2017 Sep 12. EPub ahead of print. PMID: 28898408
Schmalenberger KM, Eisenlohr-Moul TA, Surana P, Rubinow DR, Girdler SS. Predictors of premenstrual impairment among women undergoing prospective assessment for premenstrual dysphoric disorder: a cycle-level analysis. Psychol Med. 2017 Jul; 47(9): 1585-1596. PMC5486218
Eisenlohr-Moul TA, Peters JR, Pond RS Jr, DeWall CN. Both trait and state mindfulness predict lower aggressiveness via anger rumination: A multilevel mediation analysis. Mindfulness (N Y). 2016 Jun; 7(3): 713-726. PMC4943669
Eisenlohr-Moul TA, Rubinow DR, Schiller CE, Johnson JL, Leserman J, Girdler SS. Histories of abuse predict stronger within-person covariation of ovarian steroids and mood symptoms in women with menstrually related mood disorder. Psychoneuroendocrinology. 2016 May; 67: 142-52. PMC4811338
Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Leserman J, Girdler SS. Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition. Menopause. 2016 Mar; 23(3): 257-66. PMC4764412
Eisenlohr-Moul TA, DeWall CN, Girdler SS, Segerstrom SC. Ovarian hormones and borderline personality disorder features: Preliminary evidence for interactive effects of estradiol and progesterone. Biol Psychol. 2015 Jul; 109: 37-52. PMC4516641
|Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach||K99R00MH109667||CLEAR – Eisenlohr-Moul Lab||On-going|
|Using a Perimenstrual Steroid Stabilization Experiment to Validate a Smartphone-Based Assessment Protocol for Perimenstrual Mood Dysregulation and Suicidality||Gia Allemand Foundation||
||CLEAR – Eisenlohr-Moul Lab||On-going|
|04/23/2020||Steroid mechanisms of changing affective symptoms and suicide across the menstrual cycle||Past Event|
|10/02/2019||Ovarian Steroid Mechanisms in Premenstrual Exacerbation of Depression and Suicide Risk||Past Event|
|08/03/2018||Suicide Risk Assessment||Past Event|